Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuGenes01 busulfan DNA-guided first-dose study in pediatric stem cell transplantation
NL-OMON57837Recruiting
- Sponsor
- Hôpitaux Universitaires de Genève
- Start
- Sep 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of busulfan in Condition requiring hematopoietic cell transplantation and leukemia (2 arms), sponsored by Hôpitaux Universitaires de Genève. Started Sep 2025; status: recruiting.
02
Drugs
busulfan
03
Conditions
Condition requiring hematopoietic cell transplantationleukemia
Beyond the preview
Go deeper on NL-OMON57837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57837.